Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $20 price target on Iovance Biotherapeutics after its Q1 results also disclosed that 3 of its abstracts submitted to ASCO have been accepted. The analyst believes that the company's lifileucel in melanoma update has a "clear opportunity to improve", whiles its LN-145 in cervical cancer data set could be supportive of an accelerated development path. Catanzaro sees Iovance Biotherapeutics as a "best-positioned T-cell therapy" stock, with $440M in cash on hand being sufficient to fund its operations into 2022.